Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data
Evaxion (NASDAQ:EVAX) is one of the hot stocks to buy with huge upside potential.
Merck & Co. Inc. (MRK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RWC Asset Management Tord Stallvik (Ceo) | 219,482 | $18,421,124 | -7% | 0.89% |
| 2. | Bourgeon Capital John Zaro | 167,227 | $14,035,530 | +4% | 2.53% |
| 3. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 37,439 | $3,142,292 | -6% | 1.47% |
| 4. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $88.25 | 2,833 | $249,999.98 | 2,933 | 2025-02-06 | Filing | |
| $88.50 | 15,000 | $1,327,500.00 | 16,000 | 2025-02-05 | Filing | |
| $113.68 | 3 | $341.04 | 20,599 | 2023-04-26 | Filing | |
| $105.47 | 136 | $14,343.92 | 20,631 | 2023-03-20 | Filing | |
| $109.20 | 11 | $1,201.20 | 20,495 | 2023-02-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.76 | 4,262 | $352,723.12 | 7,778 | 2025-04-25 | Filing | |
| $84.09 | 8,500 | $714,744.60 | 30,705 | 2025-02-19 | Filing | |
| $85.34 | 6,000 | $512,056.80 | 24,123 | 2025-02-13 | Filing | |
| $88.76 | 2,361 | $209,550.79 | 7,085 | 2025-02-06 | Filing | |
| $125.50 | 38,291 | $4,805,520.50 | 50,908 | 2024-02-14 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,945,187 | $876,600,026 | 0.77% | |
| 2. | 8,344,126 | $700,322,495 | 0.71% | |
| 3. | 7,366,188 | $618,244,159 | 0.36% | |
| 4. | 5,496,664 | $461,335,010 | 0.63% | |
| 5. | 5,237,153 | $439,554,251 | 1.11% |
News See All
Analyst Says He’s Buying Merck (MRK) as ‘Market Turns Towards Quality’
“I think at some point the market turns towards quality. When you look at factors, this year has been about momentum. I think it’s going to turn to quality.
10 Trending Stocks This Week
The massive AI deals and capital spending plans announced by some of the top technology companies have stunned many on Wall Street, fueling concerns that we may be living through an AI bubble or caught...
11 Defensive Healthcare Dividend Stocks To Buy Now
US healthcare stocks have been under mounting pressure this year, largely due to policies introduced by the Trump administration.
13 Best Forever Stocks to Invest In Now
On October 11, Tom Lee from Fundstrat appeared on CNBC Television to discuss the recent market decline, as the S&P 500 dropped by around 2.9% on Friday, October 10.
Merck Completes $10B Acquisition of Verona Pharma, Adds COPD Drug Ohtuvayre
Merck & Co. Inc. (NYSE:MRK) is one of the best growth stocks to buy now. On October 7, Merck & Co. announced the completion of its acquisition of Verona Pharma (NASDAQ:VRNA).
Merck Initiates Three New Phase 2b Trials for Investigational Inflammatory Drug Tulisokibart
Merck & Co. Inc. (NYSE:MRK) is one of the most promising stocks under $100. On October 6, Merck & Co. announced the initiation of three new Phase 2b trials for tulisokibart (MK-7240).
12 Best Growth Stocks to Buy Now
On October 1, Keith Lerner, Chief Investment Officer at Truist Wealth, appeared on CNBC and stated that the shutdown fears are muted, and investors are not overly concerned right now.
14 Most Promising Stocks Under $100
On October 10, Tom Lee of Fundstrat joined 'Closing Bell' on CNBC to suggest that the S&P can still get to at least 7,000 this year. Tom Lee stated that markets are attempting to balance a few things.
Hedge Fund Resource Center Billionaire Hedge Funds
